CHANNELS

Subscribe to the InfoTech eNewsletter

infoTECH News

TMCNet:  Bharat Book Bureau: Daclatasvir, Asunaprevir, and Peginterferon Lambda (Hepatitis C Virus) - Forecast and Market Analysis to 2022

[December 20, 2013]

Bharat Book Bureau: Daclatasvir, Asunaprevir, and Peginterferon Lambda (Hepatitis C Virus) - Forecast and Market Analysis to 2022

(M2 PressWIRE Via Acquire Media NewsEdge) Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics.

Daclatasvir is a DAA being developed by BMS for the treatment of HCV infection. The mechanism of action of daclatasvir involves the inhibition the NS5A protein. NS5A is unique to HCV, and the protein is essential for multiple functions in the viral lifecycle, including HCV RNA replication, despite not having any enzymatic activity.

Scope - Overview of Hepatitis C, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Daclatasvir, Asunaprevir, and Peginterferon Lambda including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Daclatasvir, Asunaprevir, and Peginterferon Lambda for the top nine countries from 2012 to 2022.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China.

For more information visit : http://www.bharatbook.com/healthcare-market-research-reports/daclatasvir-asunaprevir-and-peginterferon-lambda-hepatitis-c-virus-forecast-and-market-analysis-to-20221.html OR Contact us at : Bharat Book Bureau Tel: +91 22 27810772 / 27810773 Toll Free No for USA/Canada : 1-866-279-8368 For live chat : http://bit.ly/19m3TU4 Email: info@bharatbook.com Website: www.bharatbook.com Follow us on twitter: https://twitter.com/researchbook Follow us on linkedin : http://www.linkedin.com/company/bharat-book-bureau Our Blog : http://blog.bharatbook.com/ ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.com on the world wide web. Inquiries to info@m2.com)).

(c) 2013 M2 COMMUNICATIONS

[ InfoTech Spotlight's Homepage ]


blog comments powered by Disqus

FOLLOW US

Subscribe to InfoTECH Spotlight eNews

InfoTECH Spotlight eNews delivers the latest news impacting technology in the IT industry each week. Sign up to receive FREE breaking news today!
FREE eNewsletter